ABBOTT LABORATORIES Net Income
ABBOTT LABORATORIES (ABT) reported Net Income of $1.08 billion for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-04-29
- ABBOTT LABORATORIES net income (loss) attributable to parent for the quarter ending 2026-03-31 was $1.08B, a 18.72% decline year-over-year.
- ABBOTT LABORATORIES net income (loss) attributable to parent for the quarter ending 2025-12-31 was $1.78B, a 80.76% decline year-over-year.
- ABBOTT LABORATORIES net income (loss) attributable to parent for the quarter ending 2025-09-30 was $1.64B, a 0.12% decline year-over-year.
- ABBOTT LABORATORIES net income (loss) attributable to parent for the quarter ending 2025-06-30 was $1.78B, a 36.64% increase year-over-year.
- ABBOTT LABORATORIES net income (loss) attributable to parent for fiscal 2025 was $6.52B, a 51.32% decline from fiscal 2024.
- ABBOTT LABORATORIES net income (loss) attributable to parent for fiscal 2024 was $13.40B, a 134.18% increase from fiscal 2023.
- ABBOTT LABORATORIES net income (loss) attributable to parent for fiscal 2023 was $5.72B, a 17.45% decline from fiscal 2022.
- ABBOTT LABORATORIES net income (loss) attributable to parent for fiscal 2022 was $6.93B, a 1.95% decline from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.08B 10-Q · filed 2026-04-29 | $2.85B derived: sum of 2 quarters · filed 2026-04-29 | $4.50B derived: sum of 3 quarters · filed 2026-04-29 | $6.28B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | $1.78B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $3.42B derived: sum of 2 quarters · filed 2026-02-20 | $5.20B derived: sum of 3 quarters · filed 2026-02-20 | $6.52B 10-K · filed 2026-02-20 |
| 2025-09-30 | $1.64B 10-Q · filed 2025-10-29 | $3.42B derived: sum of 2 quarters · filed 2025-10-29 | $4.75B 10-Q · filed 2025-10-29 | $13.98B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | $1.78B 10-Q · filed 2025-07-30 | $3.10B 10-Q · filed 2025-07-30 | $12.33B derived: sum of 3 quarters · filed 2026-04-29 | $13.98B derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | $1.32B 10-Q · filed 2026-04-29 | $10.55B derived: sum of 2 quarters · filed 2026-04-29 | $12.20B derived: sum of 3 quarters · filed 2026-04-29 | $13.50B derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $9.23B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $10.88B derived: sum of 2 quarters · filed 2026-02-20 | $12.18B derived: sum of 3 quarters · filed 2026-02-20 | $13.40B 10-K · filed 2026-02-20 |
| 2024-09-30 | $1.65B 10-Q · filed 2025-10-29 | $2.95B derived: sum of 2 quarters · filed 2025-10-29 | $4.17B 10-Q · filed 2025-10-29 | $5.77B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $1.30B 10-Q · filed 2025-07-30 | $2.53B 10-Q · filed 2025-07-30 | $4.12B derived: sum of 3 quarters · filed 2026-02-20 | $5.56B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $1.23B 10-Q · filed 2025-04-30 | $2.82B derived: sum of 2 quarters · filed 2026-02-20 | $4.25B derived: sum of 3 quarters · filed 2026-02-20 | $5.63B derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $1.59B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $3.03B derived: sum of 2 quarters · filed 2026-02-20 | $4.41B derived: sum of 3 quarters · filed 2026-02-20 | $5.72B 10-K · filed 2026-02-20 |
| 2023-09-30 | $1.44B 10-Q · filed 2024-10-31 | $2.81B derived: sum of 2 quarters · filed 2024-10-31 | $4.13B 10-Q · filed 2024-10-31 | $5.16B derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $1.38B 10-Q · filed 2024-07-31 | $2.69B 10-Q · filed 2024-07-31 | $3.73B derived: sum of 3 quarters · filed 2025-02-21 | $5.16B derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $1.32B 10-Q · filed 2024-05-02 | $2.35B derived: sum of 2 quarters · filed 2025-02-21 | $3.79B derived: sum of 3 quarters · filed 2025-02-21 | $5.80B derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $1.03B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $2.47B derived: sum of 2 quarters · filed 2025-02-21 | $4.49B derived: sum of 3 quarters · filed 2025-02-21 | $6.93B 10-K · filed 2025-02-21 |
| 2022-09-30 | $1.44B 10-Q · filed 2023-11-01 | $3.45B derived: sum of 2 quarters · filed 2023-11-01 | $5.90B 10-Q · filed 2023-11-01 | $7.89B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-06-30 | $2.02B 10-Q · filed 2023-08-03 | $4.46B 10-Q · filed 2023-08-03 | $6.45B derived: sum of 3 quarters · filed 2024-02-16 | $8.55B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-03-31 | $2.45B 10-Q · filed 2023-05-04 | $4.44B derived: sum of 2 quarters · filed 2024-02-16 | $6.54B derived: sum of 3 quarters · filed 2024-02-16 | $7.72B derived: sum of 4 quarters · filed 2024-02-16 |
| 2021-12-31 | $1.99B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $4.09B derived: sum of 2 quarters · filed 2024-02-16 | $5.28B derived: sum of 3 quarters · filed 2024-02-16 | $7.07B 10-K · filed 2024-02-16 |
| 2021-09-30 | $2.10B 10-Q · filed 2022-11-01 | $3.29B derived: sum of 2 quarters · filed 2022-11-01 | $5.08B 10-Q · filed 2022-11-01 | $7.24B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $1.19B 10-Q · filed 2022-08-02 | $2.98B 10-Q · filed 2022-08-02 | $5.14B derived: sum of 3 quarters · filed 2023-02-17 | $6.38B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $1.79B 10-Q · filed 2022-05-03 | $3.96B derived: sum of 2 quarters · filed 2023-02-17 | $5.19B derived: sum of 3 quarters · filed 2023-02-17 | $5.72B derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $2.16B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $3.39B derived: sum of 2 quarters · filed 2023-02-17 | $3.93B derived: sum of 3 quarters · filed 2023-02-17 | $4.50B 10-K · filed 2023-02-17 |
| 2020-09-30 | $1.23B 10-Q · filed 2021-11-03 | $1.77B derived: sum of 2 quarters · filed 2021-11-03 | $2.33B 10-Q · filed 2021-11-03 | $3.38B derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $537.00M 10-Q · filed 2021-08-04 | $1.10B 10-Q · filed 2021-08-04 | $2.15B derived: sum of 3 quarters · filed 2021-08-04 | $3.11B derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $564.00M 10-Q · filed 2021-05-05 | $1.61B derived: sum of 2 quarters · filed 2021-05-05 | $2.57B derived: sum of 3 quarters · filed 2021-05-05 | $3.58B derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $1.05B 10-K · filed 2020-02-21 | $2.01B derived: sum of 2 quarters · filed 2020-11-04 | $3.02B derived: sum of 3 quarters · filed 2020-11-04 | $3.69B 10-K · filed 2022-02-18 |
| 2019-09-30 | $960.00M 10-Q · filed 2020-11-04 | $1.97B derived: sum of 2 quarters · filed 2020-11-04 | $2.64B 10-Q · filed 2020-11-04 | $3.29B derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $1.01B 10-Q · filed 2020-07-29 | $1.68B 10-Q · filed 2020-07-29 | $2.33B derived: sum of 3 quarters · filed 2020-07-29 | $2.90B derived: sum of 4 quarters · filed 2020-07-29 |
| 2019-03-31 | $672.00M 10-Q · filed 2020-04-29 | $1.33B derived: sum of 2 quarters · filed 2020-04-29 | $1.89B derived: sum of 3 quarters · filed 2020-04-29 | $2.62B derived: sum of 4 quarters · filed 2020-04-29 |
| 2018-12-31 | $654.00M 10-K · filed 2020-02-21 | $1.22B derived: sum of 2 quarters · filed 2020-02-21 | $1.95B derived: sum of 3 quarters · filed 2020-02-21 | $2.37B 10-K · filed 2021-02-19 |
| 2018-09-30 | $563.00M 10-K · filed 2020-02-21 | $1.30B derived: sum of 2 quarters · filed 2020-02-21 | $1.71B 10-Q · filed 2019-10-31 | $886.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $733.00M 10-K · filed 2020-02-21 | $1.15B 10-Q · filed 2019-07-31 | $323.00M derived: sum of 3 quarters · filed 2020-02-21 | $926.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $418.00M 10-K · filed 2020-02-21 | -$410.00M derived: sum of 2 quarters · filed 2020-02-21 | $193.00M derived: sum of 3 quarters · filed 2020-02-21 | $476.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | -$828.00M 10-K · filed 2019-02-22 | -$225.00M derived: sum of 2 quarters · filed 2019-02-22 | $58.00M derived: sum of 3 quarters · filed 2019-02-22 | $477.00M 10-K · filed 2020-02-21 |
| 2017-09-30 | $603.00M 10-K · filed 2019-02-22 | $886.00M derived: sum of 2 quarters · filed 2019-02-22 | $1.30B 10-Q · filed 2018-10-31 | $2.10B derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-06-30 | $283.00M 10-K · filed 2019-02-22 | $702.00M 10-Q · filed 2018-08-01 | $1.50B derived: sum of 3 quarters · filed 2019-02-22 | $1.17B derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-03-31 | $419.00M 10-K · filed 2019-02-22 | $1.22B derived: sum of 2 quarters · filed 2019-02-22 | $888.00M derived: sum of 3 quarters · filed 2019-02-22 | $1.50B derived: sum of 4 quarters · filed 2019-02-22 |
| 2016-12-31 | $798.00M 10-K · filed 2018-02-16 | $469.00M derived: sum of 2 quarters · filed 2018-02-16 | $1.08B derived: sum of 3 quarters · filed 2018-02-16 | $1.40B 10-K · filed 2019-02-22 |
| 2016-09-30 | -$329.00M 10-K · filed 2018-02-16 | $286.00M derived: sum of 2 quarters · filed 2018-02-16 | $602.00M 10-Q · filed 2017-11-02 | $1.37B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $615.00M 10-K · filed 2018-02-16 | $931.00M 10-Q · filed 2017-08-02 | $1.70B derived: sum of 3 quarters · filed 2018-02-16 | $2.28B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $316.00M 10-K · filed 2018-02-16 | $1.08B derived: sum of 2 quarters · filed 2018-02-16 | $1.66B derived: sum of 3 quarters · filed 2018-02-16 | $2.45B derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $767.00M 10-K · filed 2017-02-17 | $1.35B derived: sum of 2 quarters · filed 2017-02-17 | $2.13B derived: sum of 3 quarters · filed 2017-02-17 | $4.42B 10-K · filed 2018-02-16 |
| 2015-09-30 | $580.00M 10-K · filed 2017-02-17 | $1.36B derived: sum of 2 quarters · filed 2017-02-17 | $3.66B 10-Q · filed 2016-11-03 | $4.56B derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $784.00M 10-K · filed 2017-02-17 | $3.08B 10-Q · filed 2016-08-03 | $3.98B derived: sum of 3 quarters · filed 2017-02-17 | $4.52B derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | $2.29B 10-K · filed 2017-02-17 | $3.20B derived: sum of 2 quarters · filed 2017-02-17 | $3.73B derived: sum of 3 quarters · filed 2017-02-17 | $4.20B derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | $905.00M 10-K · filed 2016-02-19 | $1.44B derived: sum of 2 quarters · filed 2016-02-19 | $1.91B derived: sum of 3 quarters · filed 2016-02-19 | $2.28B 10-K · filed 2017-02-17 |
| 2014-09-30 | $538.00M 10-K · filed 2016-02-19 | $1.00B derived: sum of 2 quarters · filed 2016-02-19 | $1.38B 10-Q · filed 2015-11-05 | $1.97B derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | $466.00M 10-K · filed 2016-02-19 | $841.00M 10-Q · filed 2015-08-04 | $1.43B derived: sum of 3 quarters · filed 2016-02-19 | $2.40B derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-03-31 | $375.00M 10-K · filed 2016-02-19 | $964.00M derived: sum of 2 quarters · filed 2016-02-19 | $1.93B derived: sum of 3 quarters · filed 2016-02-19 | $2.41B derived: sum of 4 quarters · filed 2016-02-19 |
| 2013-12-31 | $589.00M 10-K · filed 2015-02-27 | $1.55B derived: sum of 2 quarters · filed 2015-02-27 | $2.03B derived: sum of 3 quarters · filed 2015-02-27 | $2.58B 10-K · filed 2016-02-19 |
| 2013-09-30 | $966.00M 10-K · filed 2015-02-27 | $1.44B derived: sum of 2 quarters · filed 2015-02-27 | $1.99B 10-Q · filed 2014-11-06 | $3.04B derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | $476.00M 10-K · filed 2015-02-27 | $1.02B 10-Q · filed 2014-08-05 | $2.07B derived: sum of 3 quarters · filed 2015-02-27 | $4.02B derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | $545.00M 10-K · filed 2015-02-27 | $1.60B derived: sum of 2 quarters · filed 2015-02-27 | $3.54B derived: sum of 3 quarters · filed 2015-02-27 | $5.27B derived: sum of 4 quarters · filed 2015-02-27 |
| 2012-12-31 | $1.05B 10-K · filed 2014-02-21 | $3.00B derived: sum of 2 quarters · filed 2014-02-21 | $4.72B derived: sum of 3 quarters · filed 2014-02-21 | $5.96B 10-K · filed 2015-02-27 |
| 2012-09-30 | $1.94B 10-K · filed 2014-02-21 | $3.67B derived: sum of 2 quarters · filed 2014-02-21 | $4.91B derived: sum of 3 quarters · filed 2014-02-21 | |
| 2012-06-30 | $1.73B 10-K · filed 2014-02-21 | $2.97B derived: sum of 2 quarters · filed 2014-02-21 | ||
| 2012-03-31 | $1.24B 10-K · filed 2014-02-21 | |||
| 2011-12-31 | $4.73B 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |